## Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5)

| 1.  | Your Name: Brad Bauer   |     |         |
|---|---|-----|---------|
| 2.  | Your Title: Senior Vice President   |     |         |
| 3.  | The Entity(ies) You are Representing: Appriss Health  |     |         |
| 4.  | Are you testifying on behalf of the Federal, or a State or local government entity?   | Yes | No<br>X |
| 5.  | 5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.  None |     |         |
| 6. Please attach your curriculum vitae to your completed disclosure form. |   |     |         |
| Signature:  |   |     |         |

## BRAD BAUER | executive sponsor



## Highlights:

- ✓ Over 32 years of professional experience working within commercial and government healthcare and strategic partner markets.
- ✓ Over 26 years of experience working within Healthcare Information Technology solutions to help assess and mitigate risk.
- √ 15 years of experience involved in PDMP solutions
- ✓ Has been involved in 42 PDMP state projects

Mr. Brad Bauer brings over 32 years of professional experience working within commercial and government healthcare and strategic partner markets. Brad's background also includes over 26 years of experience working within Healthcare Information Technology solutions to help assess and mitigate risk. Prior to joining Appriss, Brad worked with McKesson's interoperability and healthcare technology company, RelayHealth. He worked on projects such as Provider/Supplier enrollment with CMS central office, and program integrity efforts at the federal and state Medicaid level. Brad also worked closely with the DEA, FDA, and CDC leveraging prescription drug diversion solutions on a national scale. For the past 15 years, Brad has been focused on state Prescription Drug Monitoring Programs (PDMPs) and efforts to maximize PDMP effectiveness including integration of PDMP data within the clinical workflow.